The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.

About a dozen activists from the Extinction Rebellion climate group briefly occupied the entrance lobby of French bank BNP ...

Cigna's Evernorth business caps GLP-1 drug copays at $200 or less, aiming to boost affordability for patients and cut costs for health plan sponsors.

Hims & Hers has delivered strong results and partnerships, but recent Cigna/Novo Nordisk news increases competitive risk and ...

As demand for GLP-1 weight-loss medications like Wegovy and Zepbound continues to grow in the United States, so do questions about their affordability.

Novo's Wegovy has lost market share to Eli Lilly's Zepbound, and a new head-to-head study found that Zepbound patients lost ...

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry ...